麻豆传媒

Reduced toxicity and improved convenience position new treatments for broader use

Rapid evaluation and novel therapies may improve outcomes for these patients

Ponatinib-blinatumomab led to durable remissions without transplant in most, but 13% relapsed

News, features, and commentary about cancer-related issues

Experts at ASH debate quadruplet therapy, dexamethasone modulation, and novel approaches

Response rate of 70% at day 28 with remestemcel-L

Phase III trial sparks discussion on defining and managing high-risk smoldering myeloma

News, features, and commentary about cancer-related issues

DREAMM-7 findings help pave the way for Blenrep's return

Higher response rate, PFS, OS with cilta-cel, but ide-cel had lower rate of severe toxicity

But no overall survival benefit seen in confirmatory trial

SAHARA rounds out this year's notable trials on blood transfusions in critically ill patients

Better disease outcomes, measures of cognition, and quality-of-life vs standard care, study finds

New standard of care for patients in first remission?